6 results on '"Gerassimos Tsourouflis"'
Number of results to display per page
Search Results
2. Prognostic Impact of Serum β2-Microglobulin Levels in Hodgkin Lymphoma Treated with ABVD or Equivalent Regimens: A Comprehensive Analysis of 915 Patients
- Author
-
Theodoros P. Vassilakopoulos, Maria Arapaki, Panagiotis T. Diamantopoulos, Athanasios Liaskas, Fotios Panitsas, Marina P. Siakantaris, Maria Dimou, Styliani I. Kokoris, Sotirios Sachanas, Marina Belia, Chrysovalantou Chatzidimitriou, Elianna A. Konstantinou, John V. Asimakopoulos, Kyriaki Petevi, George Boutsikas, Alexandros Kanellopoulos, Alexia Piperidou, Maria-Ekaterini Lefaki, Angeliki Georgopoulou, Anastasia Kopsaftopoulou, Kalliopi Zerzi, Ioannis Drandakis, Maria N. Dimopoulou, Marie-Christine Kyrtsonis, Panayiotis Tsaftaridis, Eleni Plata, Eleni Variamis, Gerassimos Tsourouflis, Flora N. Kontopidou, Kostas Konstantopoulos, Gerassimos A. Pangalis, Panayiotis Panayiotidis, and Maria K. Angelopoulou
- Subjects
Hodgkin’s lymphoma ,β2-microglobulin ,prognostic factors ,chemotherapy ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
The significance of serum beta-2 microglobulin (sβ2m) in Hodgkin lymphoma (HL) is controversial. We analyzed 915 patients with HL, who were treated with ABVD or equivalent regimens with or without radiotherapy. Sβ2m levels were measured by a radioimmunoassay (upper normal limit 2.4 mg/L). Sequential cutoffs (1.8–3.0 by 0.1 mg/L increments, 3.5 and 4.0 mg/L) were tested along with ROC analysis. The median sβ2m levels were 2.20 mg/L and were elevated (>2.4 mg/L) in 383/915 patients (41.9%). Higher sβ2m was associated with inferior freedom from progression (FFP) at all tested cutoffs. The best cutoff was 2.0 mg/L (10-year FFP 83% vs. 70%, p = 0.001), which performed better than the 2.4 mg/L cutoff (“normal versus high”). In multivariate analysis, sβ2m > 2.0 mg/L was an independent adverse prognostic factor in the whole patient population. In multivariate overall survival analysis, sβ2m levels were predictive at 2.0 mg/L cutoff in the whole patient population and in advanced stages. Similarly, sβ2m > 2.0 mg/L independently predicted inferior HL-specific survival in the whole patient population. Our data suggest that higher sβ2m is an independent predictor of outcome in HL but the optimal cutoff lies within the normal limits (i.e., at 2.0 mg/L) in this predominantly young patient population, performing much better than a “normal versus high” cutoff set at 2.4 mg/L.
- Published
- 2024
- Full Text
- View/download PDF
3. Real-life Experience With Rituximab-CHOP Every 21 or 14 Days in Primary Mediastinal Large B-cell Lymphoma
- Author
-
STAMATIS J. KARAKATSANIS, MARIA BOUZANI, ARGYRIS SYMEONIDIS, MARIA K. ANGELOPOULOU, SOTIRIOS G. PAPAGEORGIOU, MICHAIL MICHAIL, GABRIELLA GAINARU, GEORGIA KOURTI, SOTIRIOS SACHANAS, CHRISTINA KALPADAKIS, EIRINI KATODRITOU, THEONI LEONIDOPOULOU, IOANNIS KOTSIANIDIS, ELEFTHERIA HATZIMICHAEL, MARIA KOTSOPOULOU, MARIA DIMOU, ELENI VARIAMIS, DIMITRIOS BOUTSIS, NICK KANELLIAS, MARIA N. DIMOPOULOU, EVRIDIKI MICHALI, GEORGE KARIANAKIS, PANTELIS TSIRKINIDIS, CHRYSSA VADIKOLIA, CHRISTOS POZIOPOULOS, ANNA PIGADITOU, EFFIMIA VRAKIDOU, THEOPHANIS ECONOMOPOULOS, LYDIA KYRIAZOPOULOU, MARINA P. SIAKANTARIS, MARIE-CHRISTINE KYRTSONIS, KONSTANTINOS ANARGYROU, MARIA PAPAIOANNOU, EVDOXIA HATJIHARISSI, ELISSAVET VERVESSOU, MARIA TSIROGIANNI, MARIA PALASSOPOULOU, EKATERINI STEFANOUDAKI, PANAYIOTIS ZIKOS, PANAYIOTIS TSIRIGOTIS, GERASSIMOS TSOUROUFLIS, THEODORA ASSIMAKOPOULOU, EVGENIA VERROU, HELEN PAPADAKI, POLIXENI LAMPROPOULOU, MELETIOS-ATHANASIOS DIMOPOULOS, VASSILIKI PAPPA, KOSTAS KONSTANTOPOULOS, THEMIS KARMIRIS, PARASKEVI ROUSSOU, PANAYIOTIS PANAYIOTIDIS, GERASSIMOS A. PANGALIS, and THEODOROS P. VASSILAKOPOULOS
- Subjects
Pharmacology ,Cancer Research ,Lymphoma, B-Cell ,General Biochemistry, Genetics and Molecular Biology ,immune system diseases ,Doxorubicin ,Vincristine ,hemic and lymphatic diseases ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Prednisone ,Prospective Studies ,Rituximab ,Cyclophosphamide ,Research Article ,Retrospective Studies - Abstract
Background/Aim: Primary mediastinal large B-cell lymphoma (PMLBCL) is an aggressive B-cell non-Hodgkin lymphoma (NHL), whose prognosis has greatly improved since the incorporation of the anti-CD20 monoclonal antibody rituximab into current therapeutic regimens. Evidence, however, on the optimal time interval between consecutive chemoimmunotherapy (CIT) cycles is still scarce. This study aimed to evaluate the efficacy outcomes of the more commonly administered 3-weekly regimens to the biweekly ones in a PMLBCL patients’ population, who were mostly treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone every 21 days (R-CHOP-21) or R-CHOP-14. Patients and Methods: We retrospectively studied our cohort of consecutively treated PMLBCL patients, focusing on their treatment density, in order to determine possible differences in treatment outcomes. Results: CIT, in the form of both R-CHOP-21 as well as R-CHOP-14 (or similar regimens), is highly active in PMLBCL, with low rates of early treatment failure. In our cohort of patients, R-CHOP-14 did not result in a meaningful improvement of freedom from progression (FFP) or overall survival (OS). Conclusion: Both R-CHOP-14 and R-CHOP-21 are probably equally effective in PMLBCL, yet further, prospective, randomized studies are warranted to clarify whether dose-dense regimens can be associated with better disease control and long-term results.
- Published
- 2022
4. Curative surgery in highly selected patients with heavily pretreated, relapsed/refractory classical Hodgkin lymphoma
- Author
-
Antonios Kourtesis, Theodoros P. Vassilakopoulos, Gerassimos A. Pangalis, Phivi Rondogianni, Vassilios Papadakis, Maria K. Angelopoulou, Gerassimos Tsourouflis, Vassilios Prassopoulos, Sophia Polychronopoulou, and Maria Efstathopoulou
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,medicine.medical_treatment ,03 medical and health sciences ,0302 clinical medicine ,immune system diseases ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Classical Hodgkin lymphoma ,Humans ,Chemotherapy ,business.industry ,Lymphoma, Non-Hodgkin ,food and beverages ,Hematology ,medicine.disease ,Hodgkin Disease ,Lymphoma ,030220 oncology & carcinogenesis ,Relapsed refractory ,Curative surgery ,Hodgkin lymphoma ,business ,030215 immunology - Abstract
At least 70–80% of the patients with Hodgkin lymphoma (HL) can be cured with first-line therapy with the improvement of staging methods and the introduction of increasingly effective chemotherapy r...
- Published
- 2020
5. Development of Classic Hodgkin Lymphoma after successful treatment of primary mediastinal large b-cell lymphoma: results from a well-defined database
- Author
-
Fotios Panitsas, Christina Kalpadakis, Vassilios Xanthopoulos, Gerassimos Tsourouflis, Kostas Konstantopoulos, Eleftheria Hatzimichael, Stamatis Karakatsanis, Maria Dimou, Eleni Variamis, Maria Papaioannou, Theodoros P. Vassilakopoulos, Gerassimos A. Pangalis, Sotirios G. Papageorgiou, Ioannis Kotsianidis, Meletios A. Dimopoulos, Alexia Piperidou, Ioannis Batsis, Ioannis Vassilopoulos, Evdoxia Hadjiharissi, Themistoklis Karmiris, Theoni Leonidopoulou, Maria K. Angelopoulou, Alkistis-Kyra Panteliadou, Eirini Katodritou, Panayiotis Panayiotidis, Dimitrios Boutsis, Maria Kotsopoulou, Niki Stavroyianni, Evgenia Verigou, and Michail Michail
- Subjects
Oncology ,Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Databases, Factual ,MEDLINE ,Mediastinal Neoplasms ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Primary Mediastinal Large B-Cell Lymphoma ,Survival rate ,Hematology ,business.industry ,Follow up studies ,medicine.disease ,Prognosis ,Hodgkin Disease ,Lymphoma ,Survival Rate ,Hodgkin lymphoma ,Female ,Lymphoma, Large B-Cell, Diffuse ,business ,Follow-Up Studies - Published
- 2020
6. Rituximab monotherapy in splenic marginal zone lymphoma: prolonged responses and potential benefit from maintenance
- Author
-
Maria N. Dimopoulou, Flora N. Kontopidou, Eleni Plata, Efstathios Koulieris, Panagiotis Panagiotidis, Gerassimos A. Pangalis, Maria K. Angelopoulou, Pantelis Tsirkinidis, Xanthi Yiakoumis, Maria Moschogiannis, Dimitra Rontogianni, Penelope Korkolopoulou, Sotirios Sachanas, Panagiotis Tsaftaridis, Christina Kalpadakis, Gerassimos Tsourouflis, Helen A. Papadaki, Marina P. Siakantaris, Theodoros P. Vassilakopoulos, Marie-Christine Kyrtsonis, and Stella I. Kokkoris
- Subjects
Adult ,Male ,medicine.medical_specialty ,Immunology ,Treatment outcome ,Kaplan-Meier Estimate ,Biochemistry ,Gastroenterology ,Drug Administration Schedule ,Maintenance Chemotherapy ,03 medical and health sciences ,Remission induction ,Antineoplastic Agents, Immunological ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Progression-free survival ,Splenic marginal zone lymphoma ,Aged ,Retrospective Studies ,Maintenance chemotherapy ,Aged, 80 and over ,business.industry ,Splenic Neoplasms ,Remission Induction ,Follow up studies ,Lymphoma, B-Cell, Marginal Zone ,Cell Biology ,Hematology ,Middle Aged ,medicine.disease ,Progression-Free Survival ,Lymphoma ,Treatment Outcome ,030220 oncology & carcinogenesis ,Drug Evaluation ,Female ,Rituximab ,business ,Follow-Up Studies ,030215 immunology ,medicine.drug - Abstract
TO THE EDITOR: Treatment of splenic marginal zone lymphoma (SMZL) is not standardized due to the lack of prospective randomized trials.[1][1][⇓][2][⇓][3][⇓][4][⇓][5][⇓][6][⇓][7][⇓][8][⇓][9][⇓][10][⇓][11][⇓][12]-[13][13] After our initial 2007 paper, we now present updated data
- Published
- 2018
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.